Webinar: Beyond PSA: Utility of a Urine Gene Expression Assay for Early Detection of Prostate Cancer
Prostate cancer is a leading cause of cancer in men, affecting more than 1 million men in the world and resulting in 300,000 deaths annually. Most guidelines now support shared decision making around the question of prostate cancer early detection—but how exactly to do this remains controversial.
The conversations can be confusing, especially during a time when appointments and procedures have been cancelled and COVID-19 has upended our normal way of practicing, leaving both patients and physicians scrambling for answers. PSA remains the gold standard as a first-line screening test, but is limited in terms of specificity, especially among older men. We now have available new, non-invasive biomarkers which can help men decide whether to proceed with biopsy, in order to find high-grade, potentially lethal tumors early while minimizing over-diagnosis of low-grade, indolent tumors.
• Understand the basics of exosomes and exosome-based diagnostic tools;
• Learn why an exosome-based liquid-biomarker approach offers an ideal platform for the early risk assessment of high-grade prostate cancer;
• Compare the performance of various biomarkers and how they fit into clinical practice;
• Determine which patients would most benefit from the ExoDx Prostate (EPI) test as a risk assessment tool.